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Abstract
Purpose The drug label of sunitinib includes a warning
for concomitant use of grapefruit juice (GJ) but clinical
evidence for this drug interaction is lacking. The aim of
this study is to determine the effect of GJ, a potent intes-
tinal cytochrome P450 (CYP) 3A4 inhibitor, on steady-
state sunitinib pharmacokinetics (PK).
Methods Sunitinib PK was evaluated in eight cancer
patients receiving sunitinib monotherapy in a ‘‘4 weeks
on—2 weeks off’’ dose regimen. Serial blood samples for
PK analysis of sunitinib were collected on two separate
days. On both PK days, patients received a single oral dose
of 7.5-mg midazolam as a phenotypic probe for assessment
of intestinal CYP3A4 activity. The ﬁrst PK day was at
steady-state sunitinib PK (between days 14–20), the second
PK day was on day 28. On days 25, 26 and 27, 200-mL GJ
was consumed 3 times a day. The effect of GJ on sunitinib
exposure was assessed by comparing sunitinib PK with and
without GJ.
Results Concomitant use of GJ and sunitinib resulted in an
11% increase of the relative bioavailability of sunitinib
(P\0.05). The effect of GJ on CYP3A4 activity was con-
ﬁrmedbyanincreaseof*50%ofmeanmidazolamexposure
(AUC0–24 h) from 122.1 to 182.0 ng h/mL (P = 0.034).
Conclusion GJ consumption results in a marginal
increase in sunitinib exposure which is not considered
clinically relevant. There is no clinical evidence under-
scoring the warning in the sunitinib drug label regarding
concomitant use of GJ.
Keywords Sunitinib   Grapefruit juice  
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Introduction
Sunitinib malate (Sutent
; SU11248) is a multitarget tyro-
sine kinase inhibitor approved for the ﬁrst-line treatment of
metastatic renal cell carcinoma (mRCC) and imatinib-
resistant metastatic gastrointestinal stromal tumors (GIST)
[1–3]. The licensed dosing regimen for sunitinib is a
‘‘4 weeks on—2 weeks off’’ schedule [4]. Sunitinib is
absorbed from the gastrointestinal tract to an unknown
extent. The intake of food does not affect the pharmacoki-
netics of sunitinib [5]. Sunitinib is in vitro extensively
protein bound, has a long half-life of *50 h and a high
apparent volume of distribution of *2,000 liters [3, 6].
CYP3A4 metabolizes sunitinib into an active metabolite,
SU12662, which is further metabolized by CYP3A4 into
inactive moieties [3, 7, 8]. Sunitinib has not been described
to be a substrate of any other metabolizing enzymes besides
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of the ATP-binding cassette (ABC) drug transporters
ABCG2 and ABCB1 and showed no afﬁnity for organic
anion transporting polypeptides (OATPs). However, the
clinical relevance of these transporters needs to be inves-
tigated in vivo [9, 10].
Coadministration of ketoconazol, a potent CYP3A4
inhibitor, results in a 51% increase of the combined area
under the concentration time curve (AUC) of sunitinib and
SU12662 after a single dose of sunitinib in healthy volun-
teers [3]. This observation was extrapolated to warnings for
the potential effect of strong CYP3A4 inhibitors including
grapefruit juice (GJ) in the drug label of sunitinib [8].
GJ contains a rich mixture of several hundred ingredients
which may be responsible for the GJ—drug interaction
effect [11–14]. However, by administrating the puriﬁed
forms of the different compounds to human volunteers,
the furanocoumarins (most abundant bergamottin (BG) and
60,70-dihydroxybergamottin (DHB)) were conﬁrmed to
result in a signiﬁcant CYP3A4 inhibiting effect, and there-
fore these constituents are held responsible for GJ—drug
interactions [15–17]. GJ is an inhibitor of intestinal
CYP3A4,withlittleeffectonhepaticCYP3A4activity[18].
Grapefruit juice also appears to be an inhibitor of ABCB1
and possibly of OATP located in the intestines [17–20].
Recently, multiple oral anticancer therapies, mainly
tyrosine kinase inhibitors, are introduced, and since most of
them are substrates of CYP3A4, their drug label mentions
that grapefruit juice could increase their exposure. Notably,
only two studies have speciﬁcally determined the clinical
effect of GJ on an oral anticancer drugs (etoposide and
nilotinib), and inconsequent effects were observed, namely
a decrease in etoposide exposure but an increase in nil-
otinib exposure [21, 22]. Therefore, the evidence for GJ—
drug interaction of most anticancer drugs is lacking. Since
patients are increasingly being treated with oral anticancer
therapy in the recent years, it is highly relevant to better
understand and to determine potential GJ—drug interac-
tions of oral anticancer drugs. Therefore, in this study the
effect of concomitant use of GJ on sunitinib exposure in
patients with cancer was determined.
Materials and methods
Patients
Patientseligibleforstudyentryweretreatedwithsunitinibat
a dose level of 25–50 mg once daily in a ‘‘4 weeks on—
2 weeks off’’ regimen. The patient should have a tumor for
whichsunitinibisregisteredastheﬁrst-line(metastaticrenal
cellcarcinoma),second-line(gastrointestinalstromaltumor)
treatment or for which no treatment options were available
anymore. All patients were C18 years old and had a WHO
performance status B2 and a life expectancy of at least
12 weeks. Cytotoxic chemotherapy or radiation therapy
within 4 weeks prior to entering the study protocol was not
allowed. Concurrent use of substances known or likely to
interfere with the pharmacokinetics (PK) of sunitinib and
with CYP3A4 activity, such as ketoconazol, ﬂuconazol,
rifampicin and St. John’s wort, was not allowed within
14 days before study entry and during the study. All patients
had adequate bone marrow, renal and hepatic functions as
deﬁned by hemoglobin C6.0 mmol/L, WBC C3.0 9 10
9/L,
platelets C100 9 10
9/L, creatinine clearance C60 mL/min,
bilirubin B1.75 9 the upper limit of institutional normal
range. Prior to commencing the study, a sample size of eight
patients was determined as sufﬁcient for a paired, two-sided
analysis to detect a difference of 25% in sunitinib exposure
with a power (1-b) of 0.8, and a two-sided signiﬁcance level
(a) of 0.05. The study was approved by the institutional
ethics committee (Leiden University Medical Center, The
Netherlands), andallpatientsgave writteninformedconsent
before entering the study.
Study design
The study was designed to evaluate the effect of GJ on
steady-state sunitinib PK. All patients were treated with
commerciallyavailablehardcapsulesunitinibmalate(Pﬁzer,
Kent, United Kingdom) at an oral dose of 25/37.5/50 mg
once daily in a ‘‘4 weeks on followed by 2 weeks off’’ dose
regimen. The study was performed during one sunitinib
treatment cycle of 6 weeks. Patients were admitted to the
hospital on two separate PK days. The ﬁrst PK day was at
steady-state sunitinib PK (between day 14–20) and the sec-
ondPKdaywasonday28.Ondays25,26and27,thepatients
used 200-ml grapefruit juice of a preselected lot of com-
mercially available GJ 3 times daily. On these 3 days, suni-
tinibwassimultaneouslyusedwiththemorningconsumption
of the grapefruit juice. On both PK days, patients were given
one midazolam 7.5-mg tablet (Roche, Woerden, The
Netherlands) as a phenotypic probe to conﬁrm the inhibitory
effect of GJ on intestinal CYP3A4 activity (Fig. 1).
Selection of a grapefruit juice batch
Different batches of GJ show a considerable variability in
BG (*35 fold) and DHB (*200 fold) concentration [23].
Therefore, selecting a batch with a sufﬁcient amount of BG
and DHB to induce a clinically relevant effect on CYP3A4
substrates was necessary before the interaction study was
conducted [15].
ConcentrationsofBGandDHBwerequantiﬁedinvarious
batches of GJ from different brands using a validated high-
performance liquid chromatography—ultraviolet detection
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123(HPLC–UV) method. This assay was based on a previously
published method with minor modiﬁcations.[23]. Brieﬂy, the
juice was homogenized by shaking. GJ (0.5 mL) was mixed
with 10-lLi n t e r n a ls t a n d a r d( 1 0 0 lg/mL, in methanol)
and 2-mL ethyl acetate. Calibration standards containing
0.2–4 lg/mL BG and 0.1–2 lg/mL DHB were prepared at
the start of each analytical run. The standard stock solu-
tion contained BG and DHB (100 and 50 lg/mL in
DMSO:methanol(1:3)). The residue from the organic phase
was reconstituted with 100 lL of DMSO/acetonitril solution
(1:3v/v)and applied tothe HPLC separationsystem (Unexas
2104, Knauer, Berlin, Germany). The compounds of interest
were separated on a Hypersil ODS RP analytical column
(4.6 9 100 mm,i.d3 lm)usingthefollowinggradient[time
scale (minutes–minutes)/percentage of solvent A (water
2500/phosphoric acid 1.25)/percentage of solvent B (ace-
tonitril)]: 0-7/70/30, 7-17 70/30 ? 0/100, 17–18/0/100,
18–19 0/100 ? 70/30, 19–22/70/30. DHB, fenprocoumon
and BG eluted at 10.9, 12.8 and 16.5 min, respectively.
Linearity was conﬁrmed over the range of 0.2–24 lg/mL for
BG and 0.1–12 lg/mL for DHB. The within-day and
between-day precision and accuracy were\15%.
Pharmacokinetic sampling
Blood samples were collected on the ﬁrst and second PK
day of the study for assessing sunitinib and midazolam
plasma concentrations. Blood was collected in heparin-
containing tubes at the following time points: pre-dose, 10,
20, 40 min; 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 and 24 h after
simultaneous intake of sunitinib and midazolam. Blood
samples were centrifuged at 3,000 rpm for 10 min, the
plasma was stored in two separate tubes for the midazolam
and sunitinib analysis, and both tubes were stored at-80 ˚C
until the day of analysis.
Bioanalysis of sunitinib and midazolam
Sunitinib was measured using a validated liquid chromato-
graphic-tandem mass spectrometric (LC–MS/MS) assay,
which has been described earlier [24]. The calibration curve
of sunitinib was linear over the range of 0.2–500 ng/mL.
The within-day and between-day precision and accuracy
were\8%. The LLQ of the sunitinib assay was 0.2 ng/mL.
Midazolam was measured using a validated liquid
chromatographic-tandem mass spectrometric (LC–MS/
MS) assay. Brieﬂy, 200-ll plasma was extracted by adding
500 ll of acetonitril containing midazolam D4 (4 lg/L)
as the internal standard, followed by vortex mixing and
centrifugation at 13,000 rpm for 5 min at ambient tem-
perature. The supernatant was collected and 10-lL was
separated on an Atlantis T3 C18 analytical column
(2.1 9 50 mm, i.d 3 lm) and eluted with the following
gradient [ﬂow rate (ml/min)/time (minutes)/percentage of
solvent A (formic acid 0.1% in water)/percentage of sol-
vent B (formic acid 0.1% in acetonitril)]: 0.3/0.5/85/15/,
0.3/1/10/90, 0.3/4.3/10/90, 0.5/0.01/10/90, 0.5/0.39/85/15,
0.5/3.3/85/15, 0.3/0.05/85/15, 0.3/0.05/85/15. The efﬂuent
was monitored with a Micromass Quattro LC triple-qua-
druple mass-spectrometric detector (Waters, Milford, MA,
USA) using the electrospray positive ionization mode. The
calibration curve of midazolam was linear over the range of
1–100 ng/mL. The within-day and between-day precision
and accuracy were\5%. The LLQ of the midazolam assay
was 0.3 ng/mL.
Pharmacokinetic analysis of midazolam
Midazolam plasma concentrations were analyzed by non-
compartmental methods using WinNonlin (version 5.2.1)
(Pharsight Corporation, Mountain View, CA, USA). The
GFJ consumption 
First PK day:
Assessment of steady-state 
sunitinib PK 
Assesment of midazolam PK 
Second PK day:
Assesment of sunitinib PK 
Assement of midazolam PK 
 after three days of GFJ 
consumption  
4 1 y a D 1 y a D Day 28 
Sunitinib od 25 – 50 mg 
Day 20 
Effect of GF on sunitinib PK 
determined by comparing sunitinib 
PK with and without GFJ
Day 25 Day 26 Day 27
Effect of GF on CYP3A4 confirmed 
by comparing midazolam PK with 
and with out GFJ
Fig. 1 Study design. GFJ grapefruit juice; PK pharmacokinetics; od once daily
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123midazolam area under the concentration time curve
(AUC0–24 h) was calculated and was compared for each
patient between the ﬁrst and second PK day. Statistical
analysis included the two-sided paired Student’s t test, and
P values\.05 were considered statistically signiﬁcant. The
statistical calculations were performed using SPSS 16.0
(SPSS Inc. headquarters, Chicago, IL, USA)
Pharmacokinetic analysis of sunitinib
Sunitinib plasma concentrations were evaluated by a
population pharmacokinetic method using NONMEM
(version VI, level 1.0) (Globomax, Hanover, MD, USA).
The ﬁrst-order conditional estimation (FOCE) method of
NONMEM with interaction (INTER) between the inter-
individual and residual random effects was used [25].
Discrimination between hierarchical models was based on
comparison of the objective function values (OFV) of
NONMEM using the likelihood ratio test. A decrease in
DOFV of 6.63 was considered statistically signiﬁcant
(P\.01) [26].
A base model was developed to describe sunitinib PK,
using sunitinib concentrations obtained on the ﬁrst and
second PK day. Next, a ﬁnal model was developed by the
introduction of a GJ effect on the relative bioavailability of
sunitinib, resulting in an effect on the apparent clearance
and apparent volume of distribution and thereby exposure
to sunitinib, since it was assumed that GJ exerts its effect
only by irreversible inhibition of intestinal CYP3A4 and
possibly by inhibition of ABCB1 (Fig. 2). The recovery
half-life of CYP3A4 activity after GJ consumption was set
to 23 h [27].
The model was evaluated by goodness-of-ﬁt plots, case
deletion diagnostics and a numerical predictive check.
Moreover, a log-likelihood proﬁle was generated for the
effect size of GJ to determine the conﬁdence interval.
The effect of GJ on sunitinib bioavailability was studied
for simultaneous intake of sunitinib and grapefruit juice but
was also evaluated for sunitinib intake 7, 24, 72 h and
1 week after the last GJ consumption.
Results
Patients
Eight patients were enrolled into the study and all were
evaluable for PK analysis. Patient characteristics are
summarized in Table 1. No severe or unexpected side
effects were observed during the 3 days of GJ or midazo-
lam coadministration on both PK days.
Selection of grapefruit juice
The concentration of BG and DHB was measured in 6
different lots of GJ. BG and DHB concentrations among
the lots tested ranged from 2.6 to 11.9 mg/L and 0.4 to
8.1 mg/L, respectively. The concentration of BG and DHB
in the selected lot of GJ was 33.1 and 2.7 lmol/L,
respectively, corresponding to 2.2 mg/200 mL BG and
0.2 mg/200 mL DHB. Due to the expiry date, a second lot
of the same brand was selected for the last two patients of
the study. The concentrations in the second lot selected
were 23.5 lmol/L BG and 5.7 lmol/L DHB, correspond-
ing to 1.6 mg/200 mL BG and 0.4 mg/200 mL DHB. The
concentration of BG in both lots was sufﬁcient to induce a
signiﬁcant drug interaction [15].
Pharmacokinetic analysis of midazolam
Midazolam exposure (AUC0–24 h) increased after prior
intake of GJ. The midazolam exposure expressed as
AUC0–24 h (±standard error of the mean (SEM)) with and
without GJ was 122.1 (± 32.9) and 182.0 (± 52.2) ng h/
mL, respectively (P = .034). Therefore, midazolam expo-
sure increased with *50% by GJ, and this observation
Grapefruit 
juice
CYP3A4
activity
Sunitinib
Vd
Lag-time
ka F
CL 
Base Model  Final Model 
Fig. 2 Sunitinib
pharmacokinetic model
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123conﬁrms the inhibitory effect of GJ on CYP3A4 activity
(Fig. 3)
Pharmacokinetic analysis of sunitinib
A one-compartment model with linear elimination and
ﬁrst-order absorption adequately described the concentra-
tion–time proﬁle of sunitinib. The data did not contain
sufﬁcient information to support a two-compartment model
and this was demonstrated by a non-signiﬁcant improve-
ment (DOFV =- 0.048) of the model on introduction of a
second compartment [6]. Inclusion of an absorption lag
time signiﬁcantly improved the base model of sunitinib.
Between-subject variabilities of the absorption rate and
clearance were large (60–70%). The base model of suni-
tinib is graphically presented in Fig. 2 (left side).
In the ﬁnal model, CYP3A4 activity was depleted by
each GJ consumption (9 in total), and the activity was
restored with a half-life of 23 h (Fig. 4a) [27]. Inhibition of
CYP3A4 activity resulted in an increase in the relative
bioavailability of sunitinib (Fig. 4b). The individual pre-
dicted and measured sunitinib concentrations are depicted
for all patients (Fig. 4c). Additionally, the predicted value
and the individual measured concentration are depicted
speciﬁcally for the both sampling days (Fig. 5). Introduc-
tion of the GJ effect on the relative bioavailability of
sunitinib signiﬁcantly improved the model (DOFV =
-10.01, P\.01) and resulted in the ﬁnal model (Fig. 2).
The estimated PK parameters in the ﬁnal model are
listed in Table 2. The derived parameters are calculated
with the estimated PK parameters and represent the data
when GJ and sunitinib are used simultaneously. Goodness-
of-ﬁt plots demonstrated that the ﬁnal model adequately
described the time proﬁle of sunitinib concentrations. Case
Table 1 Patient characteristics
Characteristic Value
Number of patients 8
Sex (female/male) 1/7
Age, years* 54 (41–78)
Baseline serum renal and liver function parameters
Creatinine, lM* 77 (56–122)
Total bilirubin, lM* 9 (6–15)
ALT, units/L* 39 (18–68)
Baseline bone marrow function parameters
Hb, mM* 8.7 (7–9.4)
WBC, 9 10
9/L* 5.5 (3.5–38.2)
Thrombocytes, 9 10
9/L* 196 (149–318)
* Median values (range)
0
50
100
150
200
250
300
350
M
i
d
a
z
o
l
a
m
 
A
U
C
0
-
2
4
h
r
(
u
g
*
h
r
/
L
)
Without GJ With GJ
Fig. 3 Effect GJ on midazolam PK. Midazolam AUC0-24 h before
and after de coadministration of GJ
0
25
50
75
100
125
150
29 22 15 8 1
Treatment Day
S
u
n
i
t
i
n
i
b
 
c
o
n
c
.
 
(
n
g
/
m
L
)
0
0.2
0.4
0.6
0.8
1
1.2
29 22 15 8 1
Treatment Day
I
n
t
e
s
t
i
n
a
l
 
C
P
3
A
4
 
a
c
t
i
v
i
t
y
0
0.2
0.4
0.6
0.8
1
1.2
29 22 15 8 1
Treatment Day
R
e
l
a
t
i
v
e
 
b
i
o
a
v
a
i
l
a
b
i
l
i
t
y
A
C
B
Fig. 4 Effect of grapefruit juice on sunitinib pharmacokinetics.
a Depletion of CYP3A4 activity by grapefruit juice consumption.
b Increase in relative bioavailability of sunitinib by grapefruit juice
consumption. c Individual predicted (lines) and measured (solid
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Cancer Chemother Pharmacol (2011) 67:695–703 699
123deletion diagnostics demonstrated that the estimated GJ
effect was not highly dependent on the data from a single
patient (range in relative F = 1.05–1.14). Moreover, suit-
ability of the ﬁnal model was conﬁrmed by the results from
a numerical predictive check [28]. Out of 268 observed
sunitinib plasma concentrations, 21.6% was below the
P25–P75 (interquartile) prediction interval, 57.1% was
within the interval, and 21.3% was above the P25–P75
prediction interval.
Based on the ﬁnal model, it is determined that simul-
taneous intake of sunitinib and grapefruit juice results in a
decrease of intestinal CYP3A4 activity and consequently
an increase of sunitinib exposure of 11% (as a result of
the increased relative bioavailability 1.11, 95%CI 1.042–
1.182).
Since the intestinal CYP3A4 activity is restored with a
half-life of 23 h, the relative bioavailability of sunitinib is
also restored with a half-life of 23 h. The different time
interval evaluations resulted in the following estimates:
when GJ is consumed 7 h before the sunitinib dose, the
sunitinib exposure is increased by *8.9%, after 24 h the
effect is *5.3%, and after 72 h it is *1.3%. If sunitinib
therapy starts 1 week after the last GJ consumption, the
effect of GJ on the exposure to sunitinib is negligible
(*0.07%).
Discussion
This study shows that inhibition of the intestinal CYP3A4
activity by GJ results in a signiﬁcant but not clinically
relevant increase of sunitinib exposure. The drug label of
sunitinib mentions that GJ may increase the exposure to
sunitinib This remark, however, is based on extrapolation
of the effect of ketoconazol on sunitinib exposure after
single-dose administration, and clinical evidence for the
 Sunitinib without GJ            Sunitinib without GJ 
Time (hr)
Fig. 5 Effect GJ on sunitinib PK. The population prediction (solid
line), measured sunitinib concentration (gray dots) and 50% predic-
tion interval (grayed area) on the ﬁrst PK day (without the
coadministration of sunitinib) and second PK day (with the
coadministration of sunitinib)
Table 2 Estimated and derived sunitinib pharmacokinetic parameters in the ﬁnal model
Estimated parameters Estimate Standard error
of estimate (RSE%)
Interindividual
variability (IIV) (CV%)
Standard error
of IIV (RSE%)
Cl/F (L/h) 50.5 20.6 67.9 42.7
Vd/F(L) 3210 7.8 nd nd
ka (h
-1) 0.468 27.6 63.9 42.9
Relative F 1.11 70 nd nd
Absorption lag time (h) 0.487 6.8 nd nd
Proportional residual error (%) 16.3 22.9 nd nd
Derived parameters* Sunitinib without
grapefruit juice
Sunitinib with grapefruit juice
when simultaneously taken
AUC0–24 h (ng h/mL) 1122 (277–2399) 1245 (308–2663)
Cmax (ng/mL) 13.0 (10.0–14.6) 14.4 (11.1–16.2)
t1/2 (h) 53 (12–107)
Tmax (h) 8.2 (2.8–12.4)
RSE relative standard error; Cl/F apparent clearance; Vd/F apparent volume of distribution; ka absorption rate constant; F bioavailability; nd not
determined; AUC0–24 h area under the plasma concentration–time curve over the dose interval 0–24 h at steady-state pharmacokinetics; t1/2
elimination half-life; Tmax time to reach peak plasma concentration
Between-subject variability was assessed using exponential models
* Derived parameters are calculated from estimated parameters and are demonstrated as mean values (range)
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123presumably drug interaction between sunitinib and GJ is
lacking [3, 8]. Our study is the ﬁrst to directly investigate
the effect of GJ on sunitinib exposure in patients with
cancer and shows that there is the increase in sunitinib
exposure by GJ consumption is clinically not relevant.
Moreover, this is the third study investigating an inter-
action of GJ with oral anticancer therapy. The studies show
a reverse, relevant and irrelevant effect of GJ [21, 22].
Indeed, all eight approved tyrosine kinase inhibitors are
substrates of CYP3A4, and therefore their exposure could
be increased by the consumption of GJ. Since the tyrosine
kinase inhibitors have very different bioavailabilities, the
effect of GJ observed in our study cannot be extrapolated to
the other tyrosine kinase inhibitors so additional studies
determining the effect of GJ on the individual TKI expo-
sure should therefore be conducted.
GJ is a potent inhibitor of intestinal CYP3A4 with little,
if any, effect on the activity of hepatic CYP3A4. Indeed, a
signiﬁcant effect of GJ on the exposure to CYP3A4 sub-
strates (e.g. simvastatine, felodipine and triazolam) is seen
after oral administration, while the effect is only limited
after intravenous administration of these drugs [15, 29–31].
GJ is also an inhibitor of the drug transporters ABCB1,
OATP1A2 and OATP2B1, which could contribute to the
effect of GJ on the exposure of co-administered drugs
[13, 32–37].
Midazolam is extensively metabolized by CYP3A4 with
less afﬁnity for CYP3A5, ABCB1, ABCG2 and OATPs
[38–41]. In previous studies, GJ showed a pronounced
effect on the exposure of orally administered midazolam
[27, 31, 42]. In our study, midazolam was co-administrated
on both PK days as a phenotypic probe to conﬁrm the
decreased activity of intestinal CYP3A4 by the selected
batch of GJ.
The patients in our study consumed GJ 3 times a day for
3 days (25, 26 and 27) at steady-state sunitinib PK. On the
last sunitinib treatment day (day 28) in the 6-week treat-
ment cycle, the sunitinib PK was determined and compared
to the data obtained without consumption of GJ. The effect
of GJ was estimated on the relative bioavailability of
sunitinib, since GJ is a potent intestinal CYP3A4 inhibitor,
and therefore, only an effect on the sunitinib uptake is
expected rather than on sunitinib clearance, volume of
distribution, absorption rate constant and absorption lag
time. ‘‘In our study, we have focused on the effect of GJ, an
intestinal CYP3A4 inhibitor, on the pharmacokinetics of
sunitinib. A limited, if any, effect was expected on the
SU12662 exposure since hepatic CYP3A4 activity is not
interfered by GJ consumption and therefore only sunitinib
was quantiﬁed’’.
Indeed, the concomitant use of grapefruit juice results
in a signiﬁcant increase of 11% in sunitinib exposure.
However, since the reported interpatient variability in
sunitinib clearance is large *40%, the effect of GJ on
sunitinib exposure is negligible and should not be regarded
as clinically relevant [6]. Moreover, the marginal 11%
increase in sunitinib exposure is unlikely to result in an
increased toxicity or different anticancer efﬁcacy, although
data on the pharmacokinetic–pharmacodynamic relation-
ship are not available yet.
GJ irreversibly inhibits CYP3A4 and therefore it takes
time to restore CYP3A4 functionality since it is dependent
on formation of new enzymes. The recovery half-life of
CYP3A4 activity after consuming GJ was set at 23 h
according to the study of Greenblatt et al [14]. The
recovery half-life was conﬁrmed by several interaction
studies between midazolam and GJ over different time
intervals [31, 42, 43].
The half-life of sunitinib is relatively long (*50 h) and
therefore steady-state PK of sunitinib is reached after
*8 days. Similarly, it takes *8 days to achieve steady
state after coadministration of GJ. Therefore, at the second
PK day, after 3 days coadministration of GJ, steady-state
sunitinib was not reached. Since a large increase of suni-
tinib exposure was expected upon coadministration of GJ
and consequently more toxicity, it was considered unethi-
cal to continue coadministration until sunitinib steady state
was reached. Therefore, we chose to analyze the effect of
GJ on sunitinib PK by a compartmental PK approach. The
estimated apparent clearance and volume of distribution
found in our study are similar to those described earlier by
compartmental approach [6]. Conversely, a non-compart-
mental approach was used for determining midazolam
exposure used as a phenotypic probe. Indeed, we could
adequately determine the exposure to midazolam with and
without GJ since extensive sampling was done from the
start of midazolam administration until plasma levels of
midazolam were undetectable.
The lack of a clinically relevant effect of GJ on sunitinib
exposure was not related to the batch of GJ that was used in
this study. First, the GJ selected had a sufﬁcient content of
BG (2.2 mg/1.6 mg) to induce a signiﬁcant effect on
CYP3A4 activity [15]. Secondly, even after the recovery of
a proportion of the intestinal CYP3A4 enzymes on the
second PK day, a signiﬁcant effect *50% was observed on
the phenotypic drug midazolam, which is comparable to
the effect of GJ on midazolam exposure explored in earlier
interaction studies [27, 42]. No effect of sunitinib on
midazolam exposure was observed since midazolam
exposure was similar to the exposures reported in earlier
studies [42, 44]. The increase in midazolam exposure due
to GJ coadministration conﬁrms the signiﬁcant effect of GJ
on intestinal CYP3A4 activity. Hence, the marginal effect
observed on sunitinib bioavailability is likely to be the
result of the limited efﬁciency of sunitinib metabolism by
intestinal CYP3A4. The limited effect of GJ is in contrast
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123to the large effect (51% increase) observed after coad-
ministration of the CYP3A4 inhibitor ketoconazol [3].
Notably, the interaction study with ketoconazol was per-
formed after a single sunitinib dose, while in the current
study the interaction with GJ was determined after multiple
dosing. Inhibition of a major metabolic pathway may lead
to shunting of the metabolism to alternative metabolic
pathways at steady-state PK that remains unnoticed after
single-dose administration. Indeed, we have reported that
alternative metabolic pathways can play a dominant role
after prolonged exposure to imatinib [45]. Another expla-
nation could be that ketoconazol is a strong intestinal and
hepatic CYP3A4 inhibitor, while GJ is only capable of
inhibiting intestinal CYP3A4.
In conclusion, upon coadministration of GJ only mar-
ginally increases in sunitinib exposure were observed
which is not regarded clinically relevant.
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